Syndecan-1 shedding circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer

Docetaxel chemotherapy is a standard treatment for castration-resistant prostate cancer (CRPC). Rapidly expanding treatment options for CRPC provide reasonable alternatives for those who are resistant to docetaxel. Therefore, prediction of docetaxel resistance has become of great clinical importance. Syndecan-1 (SDC1) has been currently shown to be involved in chemotherapy resistance in various malignancies including prostate cancer. The predicting value of serum SDC1 level has not been evaluated yet.

Source: Urologic Oncology: Seminars and Original Investigations - April 5, 2018 Category: Urology & Nephrology Authors: Tibor Szarvas, Sabina Sevcenco, Orsolya M ódos, Dávid Keresztes, Péter Nyirády, András Kubik, Miklós Romics, Ilona Kovalszky, Henning Reis, Boris Hadaschik, Shahrokh F. Shariat, Gero Kramer Tags: Original article Source Type: research